|
|
|
23.04.26 - 13:33
|
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology....
|
|
|
|
|
20.04.26 - 08:01
|
Goldman sieht ernormes Potenzial bei Corvus - Anleger mit starken Nerven erwartet eine Verdopplungschance (Ariva)
|
|
|
Die Experten von Goldman Sachs trauen Corvus Pharmaceuticals mit Blick auf den Wirkstoff Soquelitinib einen kräftigen Kurssprung zu. Auch andere Analysten sehen weiteres Potenzial. Doch trotz der Euphorie bleibt die Biotech-Aktie eine hochspekulative Wette auf klinische Daten und den Erfolg in einem umkämpften Milliardenmarkt. Corvus Pharmaceuticals ist eines jener US-Biotechunternehmen, die lange unter dem Radar laufen und dann binnen weniger Monate plötzlich in den Fokus der Börse rücken. Das Unternehmen wurde 2014 gegründet, sitzt in South San Francisco und ist an der Nasdaq notiert. Operativ ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.01.26 - 23:03
|
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters′ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $201.2 million, including proceeds from the full exercise of the underwriters' option to purchase additional shares. All of the shares of common stock were offered by Corvus....
|
|
|
|
|
22.01.26 - 04:57
|
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of common stock at the public offering price, less underwriting discounts and commissions....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
